Oracle Corporation (ORCL)
Verdict history · ORCL
Every call Verdix has made on ORCL.
While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
See methodology for how verdicts are produced. Full track record →
Why the panel isn’t ready to call ORCL yet — and where they disagree.
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
NYSE · Information Technology / Software & Cloud · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
WaitHIGH confidence
Why
Oracle splits our panel between waiting and avoiding: all five voices see a quality database franchise with genuine AI-cloud optionality, but the $135 billion debt load, the Stage 4 downtrend, and Chairman Henley's insider selling keep every archetype on the sidelines at $150.52. The debate is not whether ORCL is a good business — it's whether the price and the balance sheet give shareholders a fair shot at capturing the FY2029 free-cash-flow inflection without getting diluted or caught in a credit squeeze first.Level to watch
Key support 149.03−1.0% from 150.52
Next catalyst
Line in the sand: A weekly close below the EMA200 at $149 would confirm deepening Stage 4 and open a path to the $120–122 zone where The Moat Compounder and The Asymmetric Bargainer both see genuine margin of safety.The panel's take
Verdict: WAIT · Conviction: HIGH · Last price: 150.52
This is a BUY vs WAIT split, not BUY vs SELL. Five of six voices are non-bullish, and four of those five (technical scout, fundamental scout, The GARP Operator, The Asymmetric Bargainer) explicitly say "good business, wrong price/timing" — they want ORCL, just not here. The lone business-objection voice is The Moat Compounder (leverage as dealbreaker), but even he says he'd buy below $120. The structure is unambiguous: the business is not in fundamental dispute; the entry price and absence of a bottoming catalyst are. Per Step B rule: BUY vs WAIT split synthesizes to WAIT.
Key levels
Key levels · ORCL
USD · as of 2026-08-15Analyst consensus target 150.52 USD · range 150.52–150.52
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran Oracle Corporation past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: At $150.52, ORCL sits squarely inside a $140–160 intrinsic-value range, with the DCF point estimate at $148 — essentially fair value, leaving no margin of safety for the $135B net-debt overhang and the three-year wait until FCF inflection in FY2029. Conviction: Conviction is tempered by the wide spread between bear ($110) and bull ($195) scenarios, which hinges entirely on whether the capex peak in FY2027-28 actually translates into margin expansion rather than stranded assets.
The Moat CompounderValue/Quality/Moat🔴 BearishMed
Signal: Oracle's database switching costs are genuine, but they do not offset a balance sheet carrying $135 billion in net debt at 3.89x debt-to-equity — a leverage ratio that turns equity into a call option on flawless cloud execution rather than an ownership stake in a toll-bridge business. Conviction: Certainty would require two independent signals that are both absent today: a credible multi-year debt-reduction plan and an entry price below $120 that provides genuine asset-coverage margin.
The Forensic SkepticContrarian/Forensic🔴 BearishMed
Signal: The 44% gap between the $150.52 price and the $258.50 analyst consensus target is not an opportunity — it is a warning, because Chairman Jeffrey Henley sold 281,500 shares in June while no insider has bought a single share, and the stock sits at the weekly EMA200 ($149), the last technical defense before an air gap down to $120. Conviction: Conviction stays high because three independent red flags — Stage 4 monthly trend with bearish MACD, a $20B equity-ATM dilution plan in FY2027, and negative tangible book value — reinforce each other without requiring any one of them to be perfectly timed.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: The PEG ratio of 0.66 on 19.4x forward earnings normally screams 'back up the truck,' but the $135.5B net-debt load turns that cheap multiple into a mirage — one bad quarter of cloud growth and the debt-service math overwhelms even 33% operating margins. Conviction: What holds conviction back is the absence of a single confirming signal that the downtrend is ending: no monthly close above the EMA20 ($171.76), no insider buying, and no debt-reduction catalyst on the calendar.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralMed
Signal: ORCL fails the first Dhandho principle because tails carries a 40%-probability path to $100–120 — a 30%-50% permanent loss driven by debt servicing costs and $20B of equity dilution — while the 20%-probability upside to $220+ demands three years of uninterrupted execution. Conviction: Conviction is reinforced by the Kelly-math asymmetry: the expected-value calculation stays negative as long as the Chairman is selling and the weekly EMA200 support at $149 remains untested on a closing basis.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
- All five voices agree that Oracle's core business — enterprise database with high switching costs and 33% operating margins — is a quality franchise, not a broken company. The dispute is never about whether ORCL is a good business; it is about price, timing, and leverage.
- No archetype sees a buy signal at $150.52. Even the lone non-bearish voice (The Intrinsic-Value Modeler) pegs fair value at $148 with wide uncertainty bands, offering no margin of safety.
- Every analyst flags the $135B net-debt load and the planned $40B capital raise (including $20B equity ATM) as the central risk that turns an otherwise attractive AI-cloud narrative into a wait-or-avoid situation.
- The weekly EMA200 at $149 is universally recognized as the critical technical line: a close below it opens $120–122, and a defense of it keeps the stock in a choppy holding pattern rather than a deepening Stage 4 decline.
The real debate
- The Intrinsic-Value Modeler sees $148 as fair value and would buy below $130, framing the stock as a "show me" story where the market is already pricing the risks correctly. The Forensic Skeptic counters that the balance sheet makes any DCF exercise fragile, because negative tangible book value and the $20B equity ATM mean the equity is a claim on hopes, not assets — intrinsic value could be $110 or lower if credit markets tighten.
- The GARP Operator and The Asymmetric Bargainer both want to own ORCL eventually but disagree on the trigger: The GARP Operator needs a monthly close above $171.76 (EMA20) to confirm the downtrend is stalling, while The Asymmetric Bargainer would rather see a washout to $120 where the downside is genuinely limited — two opposing entry philosophies that both point to waiting at $150.52.
- The Moat Compounder objects to the business itself — leverage as a dealbreaker — while the other cautious voices explicitly say "good business, wrong price." This is the lone business-quality dissent on an otherwise price-and-timing panel split.
The question it comes down to: Can Oracle deleverage fast enough to turn its genuine AI-infrastructure tailwind into equity value before the $135B debt load and $20B equity dilution punish shareholders who bought at $150?
The bottom line
- Line in the sand: A weekly close below the EMA200 at $149 would confirm deepening Stage 4 and open a path to the $120–122 zone where The Moat Compounder and The Asymmetric Bargainer both see genuine margin of safety.
- Trigger to turn bullish: A monthly close above the EMA20 at $171.76 with improving weekly MACD would signal the 56% drawdown is stalling, flipping The GARP Operator and The Intrinsic-Value Modeler from neutral to constructive.
- Catalyst to watch: The FY2027 $20B equity ATM program's pricing and size will reveal whether management can raise capital without cratering the stock — any increase in the planned dilution would validate The Forensic Skeptic's worst-case path.
- Debt milestone: A credible plan to reduce net debt below $100B within two years, or a credit-rating-agency upgrade on improving leverage metrics, would remove the single largest objection shared across all five non-bullish voices.
contact@verdixhq.com · Published 2026-08-15 · Prices as of 2026-08-15 · Time horizon: 3–12 months · No direct position held in ORCL · ORCL verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel also debated